227 | RITUXIMAB AND EPCORITAMAB AS FIRST‐LINE THERAPY FOR PATIENTS WITH HIGH‐TUMOR BURDEN FOLLICULAR LYMPHOMA: FIRST RESULTS OF A MULTICENTER PHASE II TRIAL
R. Merryman(Dana-Farber Cancer Institute), Yazeed Sawalha(Cleveland Clinic), Robert Redd(Harvard University), Jennifer R. Brown(Dana-Farber Cancer Institute), Oreofe O. Odejide(Dana-Farber Cancer Institute), Kami J. Maddocks(The Ohio State University), Caron A. Jacobson(Dana-Farber Cancer Institute), Erin M. Parry(Broad Institute), Sumana Devata(Medical College of Wisconsin), Amy Bessnow(Harvard University), Philippe Armand(Harvard University), Inhye E. Ahn(Dana-Farber Cancer Institute), Matthew S. Davids(Dana-Farber Cancer Institute), Christine E. Ryan(Dana-Farber Cancer Institute), C. Casulo(University of Rochester Medical Center), A. I. Kim(Dana-Farber Cancer Institute), Rosario Tringale(Dana-Farber Cancer Institute), Eric D. Jacobsen(Dana-Farber Cancer Institute), David Qualls(Memorial Sloan Kettering Cancer Center), Ann S. LaCasce(Otsuka (Japan)), Hamish Walker(Dana-Farber Cancer Institute), Jennifer L. Crombie(Dana-Farber Cancer Institute), Motohiro Murakami(Dana-Farber Cancer Institute), Vanessa Kats(Boston University), David C. Fisher(Dana-Farber Cancer Institute), Aravind Sekar, A. Sigmund(The Ohio State University), D. S. Wallace(University of Rochester Medical Center), C. K. Hahn(Dana-Farber Cancer Institute)
Cited by 1
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k